Earnings Releases·Nov 10, 2026, 4:50 PM ET

Gossamer Bio — Third Quarter 2026 Earnings Summary

Revenue from contracts with collaborators surged to $38.4 million in Q3 2026 from $13.3 million in the prior year period, driven by the termination of the Chiesi Collaboration Agreement, while R&D expenses fell to $18.8 million from $45.5 million due to reduced clinical trial costs for seralutinib.
Net loss narrowed to $48.1 million ($7.36 per share) for the quarter compared to $48.2 million ($16.92 per share) in the prior year, with the nine-month net loss improving to $77.8 million from $123.1 million, though the quarter included a non-cash $(56.5) million remeasurement of warrant liability.
Management submitted the first NDA for seralutinib to the FDA in September 2026 and targets a potential commercial launch in 2027, with FDA acceptance expected to unlock up to $125 million in additional committed capital.
The company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance and announced a structured private placement offering up to $250 million in total potential gross proceeds, with an initial $25 million closing and a second $125 million tranche contingent on FDA acceptance.